Objective: This study aims to evaluate the changes in estimated glomerular filtration rate (eGFR) and glycosylated hemoglobin (HbA1c) together with waist-to-hip ratio (WHR) and body weight (BW) in Indian patients with type 2 diabetes (T2D) treated with once weekly dulaglutide in a real-world setting.

Methodology: Patients with inadequately controlled T2D (N = 41) from a tertiary care center in India were treated with once weekly dulaglutide as an add-on medication to oral antidiabetics (OADs) with or without insulin (mean eGFR [standard deviation [SD]]: 76.11 [20.23] mL/minute in patients with <120 mL/min/1.73 m2; mean HbA1c [SD]: 9.33 [1.18] %; mean WHR [SD]: 0.96 [0.06]; mean BW [SD]: 82.44 [14.55] kg; mean BMI [SD]: 31.19 [4.29] kg/m2). A total of 5 patients presented with glomerular hyperfiltration (eGFR>120 mL/min). Improvements in eGFR, HbA1c, WHR, and BW from baseline to 6-month follow-up were analyzed using paired t test.

Results: Follow-up of 6 months with dulaglutide therapy was associated with a significant increase (P<.001) in eGFR (for patients with baseline eGFR ≤120 mL/min) with a mean increase ± standard error of the mean (SEM) of 10.39 ± 1.58 mL/min. Moreover, patients with glomerular hyperfiltration demonstrated a reduction in eGFR with a mean reduction (MR) ± SEM of 37.20 ± 1.64 mL/minute that was statistically not significant. A significant reduction (P<.001) in HbA1c, 2.45 ± 0.11% was demonstrated. In addition, a significant reduction in WHR, BW, and BMI with MR ± SEM of 0.050 ± 0.004, 6.30 ± 0.39 kg, and 2.90 ± 0.22 kg/m2, respectively was demonstrated. Adverse events (AEs) reported include nausea (n = 9), loose stools (n = 2), and loss of appetite (n = 2) that were managed with probiotics and rabeprazole as required.

Conclusion: In a real-world setting, dulaglutide as add-on therapy was well tolerated and significantly improved renal function and glycemic control along with WHR and BW in Indian patients with T2D.


S.A. Patange: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.